论文部分内容阅读
利用中国知网、万方、维普、Pub Med数据库,系统检索1949年以来关于“十八反”中大戟甘草反药组合同用的研究文献,检索文章的过程中剔除综述及临床研究类文章,选取实验研究方面的文章,总结归纳大戟甘草反药组合配伍使用的宜忌条件。结果显示对大戟与甘草配伍宜忌条件的研究多集中在配伍剂量、配伍比例、煎煮方式、给药途径、大戟品种等方面。在给药剂量方面,按照临床规定安全剂量给药时大部分表现为“不反”;而两药的倍量使用,则表现出一定的相反趋势。给药途径方面,腹腔注射是禁忌条件。而其他几方面未区分出明确的“反”与“不反”的条件。笔者认为大戟甘草能否同用不能一概而论,而是受到不同条件的限制,单一条件下得出的结果只能作为参考,而不能成为定论。且发现实验研究多在生理条件下对单纯反药组合进行探讨,希望今后病理状态下含反药组合的复方研究能引起人们的重视,使“十八反”的研究更具临床指导意义。
Using Chinese CNKI, Wanfang, VIP and Pub Med databases, we searched systematically the research literature on the combination of anti-drug compound of Euphorbia euphratica in “Eighteen Antibodies” from 1949 to 1949, Class articles, select the experimental study of the article, summed up the compatibility of the compound Euphorbia anti-drug combination of taboo conditions. The results show that the euphorbia and licorice compatibility taboo conditions more concentrated in the compatibility dose, compatibility ratio, boiling mode, route of administration, Euphorbia varieties and so on. In terms of dose, most of the safe dose when administered according to the clinical manifestations is “no anti-”; and double the use of two drugs, then showed a certain opposite trend. Routes of administration, intraperitoneal injection is taboo conditions. While several other aspects did not distinguish between clear “anti” and “not anti” conditions. I believe that the application of Euphorbia licorice can not be the same can not be generalized, but subject to different conditions, the results obtained under a single condition can only be used as a reference, but can not be conclusive. And found that the experimental study of more than purely anti-drug combination under physiological conditions to explore and hope that future pathological conditions with anti-drug combination of compound research can cause people’s attention, so that the “anti-18” research more clinical significance .